当前位置:首页 > 报告详情

Guardant-Health-.pdf

上传人: c** 编号:603948 2025-02-03 33页 2.91MB

1、Conquering Cancer with DataJ.P.Morgan Healthcare ConferenceJanuary 13,2025Safe harbor and non-GAAP disclosures 2Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws.These statements relate to future

2、events or Guardant Health,Inc.(the“Company”)s future results and involve known and unknown risks,uncertainties and other factors that may cause the actual results,levels of activity,performance or achievements of the Company or its industry to be materially different from those expressed or implied

3、by any forward-looking statements.In some cases,forward-looking statements can be identified by terminology such as“may,”“will,”“could,”“would,”“should,”“to,”“target,”“expect,”“plan,”“anticipate,”“intend,”“believe,”“estimate,”“predict,”“potential”or other comparable terminology.All statements other

4、than statements of historical fact could be deemed forward-looking,including any expectations regarding the Companys commercial engine as a force multiplier for research and development initiatives;any projections of market opportunities;statements about the Companys ability to assess potential mark

5、et opportunities or any statements about the Companys ability to successfully develop new products and services;any statements regarding expectations for future reimbursement opportunities;any statements regarding the Companys long-term expectations,including with respect to oncology,liquid biopsy,a

6、nd other aspects of the Companys industry;any statements about launching planned new products and additional laboratories,including with respect to Guardant Shield,CGP tissue assay,and laboratories outside the United States;any statements about the Companys ECLIPSE study;any statements regarding exp

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Guardant Health公司在2025年J.P. Morgan医疗保健会议上关于利用数据攻克癌症的演讲内容。主要内容包括: 1. Guardant Health的使命是通过数据守护健康,为每个人提供更多无癌时间。 2. 公司2024年业绩强劲,总收入达到5.64亿美元,同比增长31%。 3. 在治疗选择方面,Guardant 360的量价齐升,平均售价达到3000美元,并成功推出了Smart Liquid Biopsy。 4. 在筛查方面,Shield产品获得了FDA批准,并在2024年第四季度实现了16.4千次的检测量。 5. 公司预计在2028年实现自由现金流转正,2024年治疗选择业务将实现自由现金流为正。 6. 2025年,公司将在治疗选择、MRD筛查和多癌种检测等方面迎来多个关键催化剂。
癌症筛查如何改变患者生活? 液体活检如何助力癌症治疗选择? 癌症筛查技术如何实现精准医疗?
客服
商务合作
小程序
服务号
折叠